AUTL

Autolus Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↑ 6/10
  • Momentum↑ 6/10
Autolus Therapeutics sales and earnings growth
AUTL Growth
Good
  • Revenue Y/Y↑ 406.67%
  • EPS Y/Y↑ 31.97%
  • FCF Y/Y↓ -38.72%
Autolus Therapeutics gross and profit margin trends
AUTL Profitability
Neutral
  • Gross margin ↓ -61.20%
  • EPS margin↓ -439.70%
  • ROIC↓ -28.80%
Autolus Therapeutics net debt vs free cash flow
AUTL Risk
Good
  • Debt / Equity↓ 1.2
  • Debt / FCF↓ 0.8
  • Interest coverage↓ -13.9

Autolus Therapeutics stock volatility is in-line with the overall market. We give it a Good risk rating.

More Biotechnology stocks ↗